Search for lepton flavor violating decays of a heavy neutral particle in p-pbar collisions at root(s)=1.8 TeV

We report on a search for a high mass, narrow width particle that decays directly to e+mu, e+tau, or mu+tau. We use approximately 110 pb^-1 of data collected with the Collider Detector at Fermilab from 1992 to 1995. No evidence of lepton flavor violating decays is found. Limits are set on the production and decay of sneutrinos with R-parity violating interactions.Comment: Figure 2 fixed. Reference 4 fixed. Minor changes to tex

MRI in CLN2 disease patients: Subtle features that support an early diagnosis

Neuronal ceroid lipofuscinosis type 2 (CLN2) disease is a rare, paediatric-onset, neurodegenerative disorder characterised in its early stages by language delay, seizures and loss of motor function. It is rapidly progressive and ultimately results in the premature death of patients. We aim to highlight common magnetic resonance imaging (MRI) features seen in early CLN2 disease and increase disease awareness among clinicians in order to facilitate early diagnosis and treatment of patients with disease-modifying enzyme replacement therapy. We obtained MRI scans from 12 Turkish children with CLN2 disease, at symptom onset or time of diagnosis, and at various times during disease progression. Patient details including age at onset of symptoms, age at diagnosis and clinical presentation were collected. MRIs were analysed to identify common features present in patients with CLN2 disease. The median diagnostic delay in this cohort was 2 years, highlighting the need for increased disease awareness among clinicians. Key MRI features suggestive of CLN2 disease that were identified included cerebellar atrophy in 11 patients, linear hyperintensity of central white matter in 10 patients, cerebral atrophy in 8 patients and thinning of the corpus callosum in 6 patients. Thalamic hypointensity was seen in 1 patient and may also indicate CLN2 disease. It is important to consider the presenting symptoms alongside clinical test results in order to support early diagnosis of CLN2 disease. Clinical suspicion of CLN2 disease accompanied by the detection of any of the above-mentioned features on MRI should encourage healthcare professionals to test for CLN2 disease. (c) 2020 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society

Momentum distribution of charged particles in jets in dijet events in p(p)over-bar collisions at root s=1.8 TeV and comparisons to perturbative QCD predictions

Inclusive momentum distributions of charged particles in restricted cones around jet axes were measured in dijet events with invariant dijet masses in the range 80 to 600 GeV/c(2). Events were produced at the Fermilab Tevatron in p (p) over bar collisions with a center of mass energy of 1.8 TeV and recorded by the Collider Detector at Fermilab. The results were compared to perturbative QCD calculations carried out in the framework of the modified leading log approximation (MLLA) and assuming local parton-hadron duality. It was shown that the data follow theoretical predictions quite well over the whole range of the jet energies included in this analysis. We extracted the MLLA cutoff scale Q(eff) and found a value of 230+/-40 MeV. The theoretical prediction of E(jet)sin theta(c) scaling, where theta(c) is the cone opening angle, was experimentally observed for the first time. From the MLLA fits to the data, two more parameters were extracted: the ratio of parton multiplicities in gluon and quark jets, r=N-partons(g-jet)/N-partons(q-jet)=1.9+/-0.5, and the ratio of the number of charged hadrons to the number of predicted partons in a jet, K-LPHD(charged)=N-hadrons(charged)/N-partons=0.56+/-0.10

Internalized stigma in pediatric psoriasis: A comparative multicenter study

Background: Internalized stigma, adoption of negative attitudes and stereotypes of the society regarding persons' illness, has not been studied previously in pediatric psoriasis patients. Objective: We aimed to investigate the internalized stigma in pediatric psoriasis patients and to determine differences according to factors affecting internalized stigma compared to adult psoriasis patients. Methods: This multicenter, cross-sectional, comparative study included 125 pediatric (55 female, 70 male; mean age±standard deviation [SD], 14.59±2.87 years) and 1,235 adult psoriasis patients (577 female, 658 male; mean age±SD, 43.3±13.7 years). Psoriasis Internalized Stigma Scale (PISS), Dermatology Life Quality Index (DLQI), Perceived Health Status (PHS), and the General Health Questionnaire (GHQ)-12 were the scales used in the study. Results: The mean PISS was 58.48±14.9 in pediatric group. When PISS subscales of groups were compared, the pediatric group had significantly higher stigma resistance (p=0.01) whereas adult group had higher scores of alienation (p=0.01) and stereotype endorsement (p=0.04). There was a strong correlation between mean values of PISS and DLQI (r=0.423, p=0.001). High internalized stigma scores had no relation to either the severity or localization of disease in pediatric group. However, poor PHS (p=0.007) and low-income levels (p=0.03) in both groups, and body mass index (r=0.181, p=0.04) in the pediatric group were related to high PISS scores. Conclusion: Internalized stigma in pediatric patients is as high as adults and is related to poor quality of life, general health, and psychological illnesses. Unlike adults, internalized stigma was mainly determined by psoriasis per se, rather than disease severity or involvement of visible body parts, genitalia or folds. Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology

Internalized stigma in psoriasis: A multicenter study

Internalized stigma is the adoption of negative attitudes and stereotypes of the society regarding a person's illness. It causes decreased self-esteem and life-satisfaction, increased depression and suicidality, and difficulty in coping with the illness. The primary aim of this study was to investigate the internalized stigma state of psoriatic patients and to identify the factors influencing internalized stigma. The secondary aim was to identify the correlation of internalized stigma with quality of life and perceived health status. This multicentre, cross-sectional study comprised 1485 patients. There was a significant positive correlation between mean values of Psoriasis Internalized Stigma Scale (PISS) and Psoriasis Area and Severity Index, Body Surface Area, Dermatological Life Quality Index and General Health Questionnaire-12 (P < 0.001 in all). Lower percieved health score (P = 0.001), early onset psoriasis (P = 0.016), family history of psoriasis (P = 0.0034), being illiterate (P < 0.001) and lower income level (P < 0.001) were determinants of high PISS scores. Mean PISS values were higher in erythrodermic and generalized pustular psoriasis. Involvement of scalp, face, hand, genitalia and finger nails as well as arthropathic and inverse psoriasis were also related to significantly higher PISS scores (P = 0.001). Our findings imply that psoriatic patients experience high levels of internalized stigma which are associated with psoriasis severity, involvement of visible body parts, genital area, folds or joints, poorer quality of life, negative perceptions of general health and psychological illnesses. Therefore, internalized stigma may be one of the major factors responsible from psychosocial burden of the disease. © 2017 Japanese Dermatological Associatio

Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey

Background: A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs. Methods: Data for age and genetic mutations from the Cystic Fibrosis Registry of Turkey collected in 2018 were used to find out the number of patients who are eligible for modulator therapy. Results: Of registered 1488 CF patients, genetic analysis was done for 1351. The numbers and percentages of patients and names of the drugs, that the patients are eligible for, are as follows: 122 (9.03%) for ivacaftor, 156 (11.54%) for lumacaftor-ivacaftor, 163 (11.23%) for tezacaftor-ivacaftor, and 57 (4.21%) for elexacaftor-tezacaftor-ivacaftor. Among 1351 genotyped patients total of 313 (23.16%) patients are eligible for currently licensed modulator therapies (55 patients were shared by ivacaftor and tezacaftor-ivacaftor, 108 patients were shared by lumacaftor-ivacaftor and tezacaftor-ivacaftor, and 22 patients were shared by tezacaftor-ivacaftor and elexacaftor-tezacaftor-ivacaftor groups). Conclusions: The present study shows that approximately one-fourth of the registered CF patients in Turkey are eligible for modulator drugs. As, frequent mutations that CF patients have in Turkey are different from North American and European CF patients, developing modulator drugs effective for those mutations is necessary. Furthermore, as modulator drugs are very expensive currently, financial support of the government in developing countries like Turkey is noteworthy. © 2020 Wiley Periodicals LL

Search for a W(') boson decaying to a top and bottom quark pair in 1.8 TeV p(p)over-bar collisions

We report the results of a search for a W(') boson produced in p (p) over bar collisions at a center-of-mass energy of 1.8 TeV using a 106 pb(-1) data sample recorded by the Collider Detector at Fermilab. We observe no significant excess of events above background for a W(') boson decaying to a top and bottom quark pair. In a model where this boson would mediate interactions involving a massive right-handed neutrino (nu(R)) and have standard model strength couplings, we use these data to exclude a W(') boson with mass between 225 and 536 GeV/c(2) at 95\% confidence level for M(W)(')>M(nuR) and between 225 and 566 GeV/c(2) at 95\% confidence level for M(W)(')<M(nuR)

Search for the supersymmetric partner of the top quark in dilepton events from p(p)over-bar collisions at root s=1.8 TeV

We have searched for the supersymmetric partner of the top quark (stop) in 107 pb^{-1} of p-pbar collisions at \sqrt{s}= 1.8 TeV collected by the Collider Detector at Fermilab (CDF). Within the framework of the Minimal Supersymmetric extension of the Standard Model (MSSM) each of the pair-produced stops is assumed to decay into a lepton, bottom quark and supersymmetric neutrino. Such a scenario would give rise to events with two leptons, two hadronic jets, and a substantial imbalance of transverse energy. No evidence of such a stop signal has been found. We calculate a 95% confidence level (C.L.) upper limit on the stop production cross section, which excludes stop masses in the region (80<m_{\stop}<135 GeV/c^2) in the mass plane of stop versus sneutrino.Comment: 7 pages, 5 figures. Submitted to Physical Review Letter

Search for associated production of Upsilon and vector boson in p(p)over-bar collisions at root(s)over-bar=1.8 TeV

We present a search for associated production of the Y(1S) and a vector boson in 83 pb(-1) of p (p) over bar collisions at roots=1.8 TeV collected by the CDF experiment in 1994-1995. We find no evidence of the searched signal in the data, and set upper limits to the production cross sections

Central pseudorapidity gaps in events with a leading antiproton at the Fermilab tevatron (p)over-barp collider

We report a measurement of the fraction of events with a large pseudorapidity gap Deltaeta within the pseudorapidity region available to the proton dissociation products X in (p) over bar +p--&gt;(p) over bar +X. For a final state (p) over bar of fractional momentum loss xi((p) over bar) and 4-momentum transfer squared t((p) over bar) within 0.063 is found to be 0.246+/-0.001 (stat)+/-0.042 (syst) [0.184+/-0.001 (stat)+/-0.043 (syst)]. Our results are compared with gap fractions measured in minimum bias (p) over barp collisions and with theoretical expectations